Olivia Monica Sigovan1, Amine Bessaad1,
Elena Kaye2, Eric Lancelot3, Claire Corot3,
Nicolas Provost4, Zouher Majd4, Magali Breisse4,
Emmanuelle Canet-Soulas1
1CREATIS-LRMN Laboratory, Lyon1
University, Lyon, France; 2Radiology, Stanford University, United
States; 3Guerbet Group, Paris, France; 4Genfit, Lille,
France
Irbesartan
(SR 47436) is an orally active nonpeptide Angiotensin II type 1 (AT1)
receptor antagonist. We report here an USPIO-enhanced MRI follow-up study
performed on apolipoprotein (apo) E-deficient mice with the goal of following
Irbesartans therapeutic effect on the development and progression of
atherosclerotic lesions. Irbesartan lead to a marked reduction in the plaque
formation. Post USPIO T2* values measured in the vessel wall showed
significant decrease compared to baseline values, however no differences were
found between treated and not treated groups. The obtained information (from
the ascending aorta) may not be representative of the general effect of the
drug.